Renin-Angiotensin-System (RAS)-Acting Agents Market Report 2026

The renin-angiotensin-system (ras)-acting agents market size has grown strongly in recent years. It will grow from $6.11 billion in 2025 to $6.44 billion in 2026 at a compound annual growth rate (CAGR) of 5.5%. The growth in the historic period can be attributed to high hypertension prevalence, aging population growth, widespread ACE inhibitor adoption, increased cardiovascular screening, affordability of generic drugs.

The renin-angiotensin-system (ras)-acting agents market size is expected to see strong growth in the next few years. It will grow to $7.96 billion in 2030 at a compound annual growth rate (CAGR) of 5.4%. The growth in the forecast period can be attributed to chronic kidney disease burden, demand for cardiometabolic drugs, improved treatment adherence, expansion in emerging markets, combination therapy approvals. Major trends in the forecast period include increasing use of combination antihypertensive therapies, growth of long-acting cardiovascular drugs, rising focus on renal protection therapies, expansion of generic RAS drug production, shift toward fixed-dose combinations.

The rising incidence of hypertension is anticipated to fuel expansion in the market for renin-angiotensin system (RAS)-acting agents. Hypertension, known as high blood pressure, is a persistent condition where the pressure of blood against artery walls remains excessively elevated. Rates of hypertension are climbing due to poor dietary habits, especially those rich in salt and processed foods, which raise blood pressure and burden the cardiovascular system. Renin-angiotensin system (RAS)-acting agents combat hypertension by controlling blood pressure via blockade of angiotensin II, a hormone that narrows blood vessels and promotes fluid buildup, thus encouraging vessel relaxation and blood pressure reduction. For instance, in September 2025, the World Health Organization - a Switzerland-based intergovernmental body - reported that roughly 1.4 billion adults aged 30-79 globally had hypertension in 2024, representing about 33% of this demographic. Hence, the growing burden of hypertension is spurring demand for renin-angiotensin system (RAS)-acting agents.

Major companies in the renin-angiotensin system (RAS)-acting agents market are prioritizing the development of innovative renin-angiotensin system (RAS) inhibitors, including angiotensin-converting enzyme (ACE) inhibitors, to boost effectiveness, reduce adverse effects, enhance patient adherence, and address conditions like hypertension, heart failure, and kidney disorders. An angiotensin-converting enzyme (ACE) inhibitor is a drug that reduces blood pressure by inhibiting the enzyme responsible for transforming angiotensin I into angiotensin II, a compound that constricts blood vessels. For example, in November 2023, Proveca Ltd., a UK-based pharmaceutical firm, secured a grant from the European Commission for pediatric use marketing authorization (PUMA) of Aqumeldi (enalapril maleate) orodispersible tablets, approved for treating heart failure in children from birth to under 18 years. Aqumeldi, an angiotensin-converting enzyme (ACE) inhibitor, manages heart failure in pediatric patients by inhibiting the angiotensin-converting enzyme (ACE), which stops the conversion of angiotensin I to angiotensin II, thus relaxing blood vessels, enhancing blood flow, and easing the heart's workload.

In February 2023, AstraZeneca, a UK-based pharmaceutical company, acquired CinCor Pharma for $1.3 billion. Through this acquisition, AstraZeneca seeks to bolster its cardiorenal pipeline by incorporating CinCor’s lead candidate, baxdrostat (CIN-107), a selective aldosterone synthase inhibitor (ASI) aimed at reducing blood pressure in patients with treatment-resistant hypertension. CinCor Pharma, a US-based biopharmaceutical company, focuses on developing renin-angiotensin-system (RAS)-acting agents, including baxdrostat, a selective aldosterone synthase inhibitor for resistant hypertension.

Major companies operating in the renin-angiotensin-system (ras)-acting agents market are Novartis AG, AstraZeneca plc, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Aurobindo Pharma Limited, Cipla Limited, Dr. Reddy’s Laboratories Ltd., Glenmark Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Pfizer Inc., Sanofi S.A., Bayer AG, Daiichi Sankyo Company Limited, Astellas Pharma Inc., Biocon Limited, Lupin Limited, Sun Pharmaceutical Industries Ltd., Mylan N.V., Zydus Lifesciences Limited.

North America was the largest region in the renin-angiotensin-system (RAS)-acting agents market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the renin-angiotensin-system (ras)-acting agents market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the renin-angiotensin-system (ras)-acting agents market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the renin-angiotensin system acting agents market by increasing the cost of imported APIs, intermediates, and formulation excipients used in cardiovascular drug manufacturing. These impacts have been most pronounced in branded ACE inhibitors and ARBs, particularly in north america and europe where API sourcing is globally diversified. Asia-pacific producers have experienced pricing pressures due to raw material imports. However, tariffs have supported domestic generic manufacturing and localized API synthesis, enhancing long-term supply security.

The renin-angiotensin-system (ras)-acting agents market research report is one of a series of new reports that provides renin-angiotensin-system (ras)-acting agents market statistics, including renin-angiotensin-system (ras)-acting agents industry global market size, regional shares, competitors with a renin-angiotensin-system (ras)-acting agents market share, detailed renin-angiotensin-system (ras)-acting agents market segments, market trends and opportunities, and any further data you may need to thrive in the renin-angiotensin-system (ras)-acting agents industry. This renin-angiotensin-system (ras)-acting agents market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

RAS-acting agents are a group of drugs that control blood pressure, fluid levels, and blood vessel tone by acting on key elements of the renin-angiotensin system, which is vital for heart and kidney health. Doctors often prescribe them for hypertension, heart failure, and chronic kidney disease because they either prevent angiotensin II formation or block its actions on blood vessels.

The primary drug categories among renin-angiotensin-system (RAS)-acting agents include angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), renin inhibitors, aldosterone antagonists, and additional types. Angiotensin-converting enzyme (ACE) inhibitors are drugs that inhibit the enzyme converting angiotensin I to angiotensin II, a compound that constricts blood vessels and raises blood pressure. They treat conditions like hypertension, heart failure, chronic kidney disease, diabetic nephropathy, and coronary artery disease, and reach patients via hospital pharmacies, retail pharmacies, online pharmacies, and specialty clinics serving end users such as hospitals, research institutes, pharmaceutical companies, and more.

The renin-angiotensin system (RAS)-acting agents market consists of sales of enalapril, lisinopril, ramipril, and captopril. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.